BK vs COLL · P/E 17, rev $20.08B vs P/E 17, rev $181.9M
The Bank of New York Mellon Corporation (BK) versus Collegium Pharmaceutical Inc (COLL) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
BK currently screens at market cap $94.14B and trailing P/E 17.0. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Not investment advice. Open the BK and COLL stock pages for the full models.
Not investment advice.